AASCIT - Journal -Reviewers

Individual Information

Jayakanth Kankanala

Center for Drug Design, University of Minnesota

Educational Qualification
From 09/2007 to 06/2011, PhD in Organic and medicinal Chemistry , University of Leeds, United Kingdom
From 06/2004 to 04/2006, MSC in Organic Chemistry , INDIA
From 06/2001 to 04/2004, BSC in Chemical Technology , INDIA
Research Interests
Medicinal chemistry, organic synthesis, heterocyclic chemistry, Drug design, Molecular modeling, virtual highthroughput screening, Pharmacokinetics, proteins
Work Experience
From 11/2013 to present, Postdoctoral research fellow , Center for Drug Design, University of Minnesota
From 09/2011 to 11/2013, Postdoctoral research associate , Medicinal chemistry and chemical biology, University of Leeds
From 10/2010 to 07/2011, Research associate , University of Leeds
From 05/2006 to 08/2007, Research Chemist , Dr Reddy's Research Laboratories Ltd
Selected Publications

Books

1.	Antony M. Latham, Jayakanth Kankanala, Dr. Vas Ponnambalam; Receptor tyrosine kinase inhibitors. Encyclopedia of Cancer; accepted; In production.
2.	Antony M Latham, Jayakanth Kankanala, Colin W G Fishwick and Sreenivasan Ponnambalam; “Identification of Receptor Tyrosine Kinase Inhibitors Using Cell Surface Biotinylation and Affinity Isolation”. VEGF Signaling: Methods and Protocols, Methods in Molecular Biology, vol. 1332, 2015.

Journal Articles

1.	o J Kankanala, A Latham, C W G Fishwick et.al; A combinatorial in silico and cellular approach to identify a new class of compounds that target VEGFR2 receptor tyrosine kinase activity and angiogenesis. Br J Pharmacol. 2012 May; 166(2): 737-48.
2.	o A.M Latham, J Kankanala and Fishwick, Colin W.G et.al; Differential sensitivity of VEGFR2 and FGFR1 receptor tyrosine kinases to indolinones and anilinopthalazines in primary endothelial cells. Br J Pharmacol. 2012 Jan; 165(1):245-59.
3.	o A Latham, J Kankanala, S Ponnambalam et.al; "In Silico Design and Biological Evaluation of a Dual Specificity Kinase Inhibitor Targeting Cell Cycle Progression and Angiogenesis"-Plos one; NOV 2014; DOI: 10.1371/journal.pone.0110997.
4.	o Toshana L. Foster, Gary S. Thompson, Arnout Kalverda, Jayakanth Kankanala, Richard Foster, & Stephen Griffin et.al; “The Solution Structure of Monomeric Hepatitis C Virus p7 Yields Potent Inhibitors of Virion Release”; Hepatology 59 (2), 408-422, 2014.
5.	o G Packer, K Lepre, J Kankanala, V Sridharan; Bimetallic (Cu/Pd) catalytic cascade reactions to 3, 3-disubstituted oxindole analogues; RSC Advances, 4 (7), 3457-3460, 2014.
6.	o Vernekar, Sanjeev; Liu, Zheng; Nagy, Eva; Miller, Lena; Kirby, Karen; Wilson, Daniel; kankanala, jayakanth; Sarafianos, Stefan; Parniak, Michael; Wang, Zhengqiang; Design, Synthesis, Biochemical and Antiviral Evaluations of C6 Benzyl and C6 Biarylmethyl Substituted 2-Hydroxylisoquinoline-1,3-diones: Dual Inhibition against HIV Reverse Transcriptase-Associated RNase H and Polymerase with Antiviral Activities. J. Med. Chem., 2015, 58 (2), pp 651–664.
7.	o SKV Vernekar, L Qiu, J Zhang, J Kankanala, H Li, RJ Geraghty, Z Wang; 5'-Silylated 3'-1, 2, 3-triazolyl thymidine analogues as inhibitors of West Nile virus and Dengue virus. J. Med. Chem., 2015, 58 (9), pp 4016–4028.

Conference Papers

1.	Jayakanth Kankanala, Colin W. Fishwick, A. P Johnson; Poster presented on “Structure based drug design and synthesis of potential anti-angiogenic drug leads”. 239th ACS National Meeting, San Francisco, CA, United States, March 21-25, 2010 (2010), MEDI-375.
2.	Presented a poster titled “Structure based drug design and synthesis of potential anti-angiogenic drug leads” at RSC bio-organic conference at University of Nottingham, UK, April 2010.
3.	Presented an oral talk titled “Design, synthesis & biological evaluation of novel inhibitors of FGFR3 & VEGFR2 kinases” at the postgraduate conference at University of Leeds, UK, June 2010 and won best presentation award.
4.	Poster presented titled “Design, synthesis and biological evaluation of novel inhibitors of anti-angiogenic agents using in silico methods” at RSC northeast organic regional meeting at Northumbria University, New castle, UK in April 2011.
5.	Presented poster titled “Design, synthesis and biological evaluation of novel inhibitors of anti-angiogenic agents using in silico methods” at RSC bio-organic conference at Burlington House, London, UK in April 2011.
6.	E Smith, J Spencer, M Ali, M Abdinejad, J Kankanala, C Fishwick, H Philippou; Elucidating novel urokinase-type plasminogen activator inhibitors; XXIII Congress of The International Society on Thrombosis and Haemostasis; 2012, Kyoto, Japan.
7.	Selected for “set for Britain” competition to present a poster at the House of Commons London, UK titled “Can small molecules aid in combating the most lethal cancer in the UK” in March 2012, London.
8.	Claire Scott ,Toshana Foster, Jayakanth Kankanala, Wendy Barclay, Richard Foster, Stephen Griffin; Poster Presentation on “Novel inhibitors of the drug-resistant M2 proton channel from pandemic swine influenza”. Influenza 2014, 09-11 September 2014, Oxford, UK.
9.	Claire Scott, Toshana Foster, Jayakanth Kankanala, Ruth Elderfield, Wendy Barclay, Richard Foster, Stephen Griffin; Poster presentation titled “Structure-guided design of novel inhibitors targeting the drug resistant M2 proton channel of swine influenza”. Society for General Microbiology, Annual Conference 2015, At BIRMINGHAM, THE INTERNATIONAL CONVENTION CENTRE, UK.
10.	Joseph Shaw, Jayakanth Kankanala, Rajendra Gosain, Richard Foster, Stephen Griffin; Poster presentation titled " Robust determination of structure activity relationships for a potent series of inhibitors targeting the hepatitis C virus P7 viroporin”. Society for General Microbiology, Annual Conference 2015, At BIRMINGHAM, THE INTERNATIONAL CONVENTION CENTRE, UK.